Company: NCEL
Filing Date: 2025-06-09
Form Type: F-4/A
Source: 0001213900-25-052354
Chunk: 56

Company: NewcelX Ltd.
Filing Date: 2025-06-09
Form: F-4/A
Chunk 56
---
ation of the Merger” beginning on page 155 of this proxy statement/prospectus, or (ii) on such other date as agreed to by the parties to the Merger Agreement in writing, in each case, subject to the satisfaction or waiver of the closing conditions. The Merger Agreement may be terminated by NLS and/or Kadimastem if the Closing has not occurred by June30, 2025. NLS and Kadimastem anticipate that the consummation of the Merger will occur in the second quarter of 2025. However, because the Merger is subject to a number of conditions, neither NLS nor Kadimastem can predict exactly when the Closing will occur or if it will occur at all. For a description of the conditions to the completion of the Merger, see the section titled “ Conditions to the Consummation of the Merger” beginning on page 155 of this proxy statement/prospectus. Q.What do I need to do now? NLS and Kadimastem urge you to read carefully and consider the information contained in this proxy statement/prospectus, including the annexes, and to consider how the Merger will affect you as a shareholder of NLS. Shareholders should then vote as soon as possible in accordance with the instructions provided in this proxy statement/prospectus and on the enclosed proxy card. Q.How do I vote at the NLS Meeting? Shareholders can either vote by personal participation or by representation. All shareholders attending the NLS Meeting (either by personal participation or representation) are requested to complete and sign the registration form, attached as an exhibit to this proxy statement/prospectus and the invitation to the NLS Meeting, latest until, 2025 (received by 11:59 pm CET) and send it either via postal mail (NLS Pharmaceutics Ltd., Alexander Zwyer, The Circle6, 8058 Zurich, Switzerland) or e -mail(acz@nls -pharma.com) to NLS. In the event that you do not intend to participate personally in the NLS Meeting, you may be represented by the independent proxy, KBT Treuhand AG Zürich, Kreuzplatz5, 8032 Zurich, Switzerland (represented by David Maillard) or a third party (who need not to be a shareholder) by completing and signing the respective power of attorney (proxy card). xv The independent proxy will be physically present at NLS Meeting to vote on behalf of the shareholders